StockDuty ← Dashboard Nov 04, 2026 12:27 AM ET
SignalEarnings

Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion

Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion

What happened: Vertex Pharmaceuticals ($VRTX) reported third-quarter 2026 revenue growth of 12% year over year, driven by its cystic fibrosis franchise and newer therapies, and raised its full-year revenue guidance following the Crinetics Pharmaceuticals acquisition. Key numbers: Revenue $3.44 billion vs. Why it matters: Higher operating expenses and Crinetics acquisition costs weighed on profitability, and management flagged that financing and integration costs could continue affecting near-term earnings. The raised guidance includes an anticipated $40-$50 million PALSONIFY contribution. Market: -4.0% today ($530.76), +17.4% YTD, 1.5x vol — as of 22:46 UTC Verified: Q3_2026 (Nov 2) EPS $4.76 vs $4.75 est, +0.2% beat; next print ~Feb 1 Coverage: 3 outlets in 24h
Vertex Pharmaceuticals ($VRTX) reported third-quarter 2026 revenue growth of 12% year over year, driven by its cystic fibrosis franchise and newer therapies, and raised its full-year revenue guidance following the Crinetics Pharmaceuticals acquisition.
Higher operating expenses and Crinetics acquisition costs weighed on profitability, and management flagged that financing and integration costs could continue affecting near-term earnings. The raised guidance includes an anticipated $40-$50 million PALSONIFY contribution. Market: -4.0% today ($530.76), +17.4% YTD, 1.5x vol — as of 22:46 UTC Verified: Q3_2026 (Nov 2) EPS $4.76 vs $4.75 est, +0.2% beat; next print ~Feb 1
Sources